PHENOTYPIC CLUSTERS OF RHEUMATIC/SYSTEMIC IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES (IMMUNOCANCER INTERNATIONAL REGISTRY)

OLIVER LAMBOTTE; MARIA SUAREZ-ALMAZOR; CHIARA BALDINI; HENDRIK SCHULZE-KOOPS; PILAR BRITO-ZERÓN; SOLEDAD RETAMOZO; MICHAEL RICHTER; JEAN-MARIE MICHOT; MARTE SCHRUMPF-HEIBERG; PETER OLSSON; GABRIELA HERNANDEZ-MOLINA; ILDIKO FANNY HORVÁTH; MUNTHER KHAMASHTA; MARIE KOSTINE; CLIFTON BINGHAM; THIERRY SCHAEVERBEKE; JAN LEIPE; ALEJANDRA FLORES-CHÁVEZ; GUSTAVO CITERA; MERAV LIDAR; DAVID LIEW; PHILIPPE GUILPAIN; YASUNORI SUZUKI; VIRGINIA FERNANDES MOÇA TREVISANI ; NAOTO AZUMA; XAVIER MARIETTE; MANUEL RAMOS-CASALS; LEONARD CALABRESE; TIMOTHY R. RADSTAKE; JACQUES-ERIC GOTTENBERG; CASSANDRA CALABRESE; BELCHIN KOSTOV; EVA AGUILAR; BENJAMIN FISHER; RUSSELL BUCHANAN; DEBASHISH DANDA; SAADETTIN KıLıÇKAP; SONJA PRAPROTNIK; BERKAN ARMAGAN

Madrid

Congreso; EULAR 2019 ? Annual European Congress of Rheumatology; 2019

The European League Against Rheumatism (EULAR)

Background: The ImmunoCancer International Registry is a Big DataSharing multidisciplinary network focused on the research of the immunerelated adverse events (irAEs) related to cancer immunotherapies (CIs).Objectives: To analyse the worldwide scenario of rheumatic/systemicautoimmune diseases (RSirAEs) associated with the use of CIs duringthe last 20 years.Methods: The first objective was to develop a systematic literature reviewcrossing the CIs terms with rheumatic and systemic autoimmune diseasesusing MedDRAVR 15.0 terms.Results: RSirAEs were identified in 11% of 12648 patients with irAEs,including 1435 cases (30% fulfilled criteria for a systemic disease) thatwere classified in 5 phenotypic clusters: Non-characterized cases included myositis (25%), arthritis (12%), arthralgias (8%), sicca syndrome (7%) and vasculitis (6%); sarcoidosis (6%),myasthenia gravis (5%), polymyalgia rheumatica (4%), leukocytoclasticvasculitis (3%) and giant cell arteritis (2%) were the most frequent systemic diseases identified:: In comparison with patients with organ-specific irAEs, RSirAEs weremore frequently associated with combined therapies (OR 2.46, CI 2.16-2.81), checkpoint inhibitors -ICis- (OR 4.01 vs TKis, CI 3.26-4.92), andPD-1is (OR 2.46 vs CTLA4is, CI95% 2.16-2.81)Conclusion: Rheumatic/systemic irAEs can be divided into 5 phenotypicclusters: articular, muscular, granulomatous, vasculitic and systemic. Thesefindings must be confirmed in real-life patients, and an international datasharing ICIR registry is planned to be launched.